18F-FLUC-CEST PET/MR in Patients With Brain Mets

Description

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining. Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.

Conditions

Brain Metastasis, Radiation Therapy, Immunotherapy, Active

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining. Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.

Use of Amide-CEST MRI and 18F-Fluciclovine PET for Discerning Tumor From Treatment Change in Patients With Brain Metastases Undergoing Immunotherapy

18F-FLUC-CEST PET/MR in Patients With Brain Mets

Condition
Brain Metastasis
Intervention / Treatment

-

Contacts and Locations

Madison

University of Wisconsin, Madison, Wisconsin, United States, 53705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 years or older
  • * Able and willing to provide informed consent
  • * Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI
  • * Received radiation therapy at some point in the last 2 years
  • * Is currently being treated with or has been treated with any other concurrent systemic therapy (multi-modal therapy) in the past 6 months, which would include immunotherapy, targeted therapy, or systemic chemotherapy, immunotherapy, or chemotherapy following radiation therapy.
  • * Has had at least one previous standard-of-care MRI imaging within the past 60 days for assessment of disease location and extent with increasing enhancement where the question of tumor recurrence versus treatment related change are a clinical question.
  • * Be able to lie still for 30-60 minutes during the imaging procedure
  • * Willing and able to undergo PET/MRI
  • * Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:
  • * The subject has their own prescription for the medication
  • * The informed consent process is conducted prior to the self-administration of this medication
  • * They come to the research visit with a driver
  • * Subject unable or unwilling to provide informed consent
  • * Subject is pregnant
  • * Subject with contraindication(s) to or inability to undergo a PET or MRI
  • * Known allergy to 18F-Fluciclovine or any of its excipients

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Michael Veronesi, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

2025-12